PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET.
A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Princeton, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 6.86; value investors should take notice.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $2.46 per share. IART also boasts an average earnings surprise of +19.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IART should be on investors' short list.
A month has gone by since the last earnings report for Integra LifeSciences (IART - Free Report) . Shares have lost about 1.6% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Integra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Integra's Q2 Earnings Top Estimates Integra LifeSciences Holdings Corporation reported second-quarter 2026 adjusted earnings per share of 56 cents, up 24.4% year over year. The figure beat the Zacks Consensus Estimate by 16.7%.
GAAP earnings per share were 6 cents in the quarter compared with the year-ago period’s loss of $6.31 per share.
Revenues of $418.76 million increased 0.8% and missed the consensus mark by 0.2%.
IART’s Specialty Surgery Posts Growth
Specialty Surgery revenues totaled $309.3 million, up 1.7% on a reported basis and 1.6% organically. Neurosurgery sales increased 1.9% organically, driven by Certas Plus, Bactiseal and CUSA as supply reliability and fulfillment improved. Instruments advanced 3.2% organically. ENT sales declined 1.9% organically as growth in MicroFrance ENT instruments was offset by weakness in other products. Management said reimbursement pressure on sinus balloons continued, while overall procedure demand remained generally consistent with its expectations.
Integra’s Tissue Reconstruction Faces Pressure
Tissue Reconstruction revenues were $109.5 million, down 1.9% on a reported basis and 2.0% organically. Wound Reconstruction declined in the mid-single digits, with growth in DuraSorb and the PriMatrix relaunch offset by lower MicroMatrix and Integra Skin sales. Integra Skin improved sequentially but faced a difficult year-ago comparison that included backorder clearance. Management said wound reconstruction was roughly flat for the first half of 2026 and remained within the range contemplated in the full-year outlook.
IART’s Margin Performance
In the reported quarter, adjusted gross profit totaled $256.9 million, up 1.8% year over year. The adjusted gross margin expanded 60 basis points (bps) to 61.3%. Selling, general and administrative expenses decreased 4.1% to $172.4 million, while research and development expenses fell 10.2% to $24.3 million.
Adjusted EBITDA was $78.4 million, up 10.1% year over year. The adjusted EBITDA margin expanded 160 bps to 18.7%, reflecting manufacturing efficiencies, lower remediation spending and benefits from the company’s margin-improvement initiatives.
IART’s Financial Position
Integra exited the second quarter of 2026 with approximately $214.4 million in cash and cash equivalents compared with $236.8 million at the end of the first quarter.
Cumulative net cash provided by operating activities at the end of the second quarter was $32.6 million, compared with the cash outflow of $2.3 million a year ago.
Integra Provided 2026 & Q3 Guidance
For full-year 2026, the company expects reported revenues to be in the range of $1.654-$1.695 billion, reflecting reported growth of 1.1% to 3.7%. The company reaffirmed its organic revenue growth guidance of 0.8% to 3.3%. Meanwhile, adjusted earnings per share are expected to be between $2.40 and $2.50.
For the third quarter of 2026, Integra expects reported revenues in the range of $410-$425 million, representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. Adjusted earnings are expected to be in the range of 53-61 cents per share.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates review.
VGM ScoresCurrently, Integra has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Integra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerIntegra is part of the Zacks Medical - Instruments industry. Over the past month, Intuitive Surgical, Inc. (ISRG - Free Report) , a stock from the same industry, has gained 4%. The company reported its results for the quarter ended June 2026 more than a month ago.
Intuitive Surgical reported revenues of $2.89 billion in the last reported quarter, representing a year-over-year change of +18.5%. EPS of $2.80 for the same period compares with $2.19 a year ago.
Intuitive Surgical is expected to post earnings of $2.61 per share for the current quarter, representing a year-over-year change of +8.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
Intuitive Surgical has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Key Takeaways IART began building SurgiMend inventory for a phased fourth-quarter 2026 relaunch.Integra expects SurgiMend share recapture to build gradually, making 2027 the key recovery year.Integra expects FDA approval earlier in 2027, pending a successful Braintree pre-approval inspection. Integra LifeSciences Holdings Corp. (IART - Free Report) has begun producing SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. That milestone adds another product-restoration catalyst to the company’s Tissue Reconstruction recovery plan.
The near-term financial effect should be limited. Management assumes no meaningful SurgiMend contribution in 2026, leaving 2027 as the more important period for judging share recapture, regulatory progress and the broader portfolio recovery.
Image Source: Zacks Investment Research
IART’s Braintree Site Starts Building InventoryBraintree began production in June 2026, giving Integra a manufacturing path to restore SurgiMend after a prolonged disruption. Management is building inventory ahead of a controlled relaunch and expects sufficient supply to support the initial rollout.
The company plans to engage historical high-volume users and key opinion leaders first, applying lessons from the PriMatrix return. Because 2026 guidance includes no meaningful SurgiMend revenues, the current inventory build is more relevant to medium-term portfolio recovery than to this year’s growth.
Integra Expects a Gradual SurgiMend Revenue ReturnManagement expects SurgiMend share recapture to build over several quarters rather than rebound immediately. On the latest earnings call, it discussed a modest recovery toward roughly 50% of the product’s historical performance of about $40 million, providing a framework for how the relaunch could develop.
That pace makes 2027 central to the investment case. The Zacks Consensus Estimate calls for 2027 revenues of $1.737 billion, up from $1.677 billion in 2026. SurgiMend would be one contributor to that expected growth, but the company has not provided formal 2027 guidance.
Image Source: Zacks Investment Research
IART’s FDA Timeline Remains the Critical GateThe December 2024 FDA warning letter remains unresolved, and related Class III premarket approvals cannot be approved until the relevant violations are corrected. Integra expects all warning-letter action items to be implemented by the end of 2026, but inspection and approval timing remains under FDA control.
SurgiMend’s clinical safety and efficacy review is complete, and management says an approvable FDA decision is already in place. The remaining premarket approval depends on a successful pre-approval inspection at Braintree, with management expecting approval earlier in 2027.
Integra’s Tissue Portfolio Could Broaden the RecoverySurgiMend would join a Tissue Reconstruction recovery already supported by DuraSorb growth and the PriMatrix relaunch. Roughly nine months after its return, PriMatrix had recovered slightly more than half of pre-recall revenues and continued to improve sequentially. MediHoney is also expected to return in 2027.
The competitive backdrop remains active. AbbVie Inc. (ABBV - Free Report) markets the AlloDerm Select regenerative tissue matrix for tissue repair and certain post-mastectomy breast reconstruction uses. Becton, Dickinson and Company (BDX - Free Report) offers Phasix Mesh for soft tissue reconstruction. Integra therefore needs product restoration to translate into sustained commercial execution, especially after Tissue Reconstruction revenues declined 2% organically in the second quarter.
IART’s Scores Keep the Relaunch in PerspectiveSurgiMend can strengthen Integra’s 2027 recovery path if the relaunch progresses as planned, but the opportunity still depends on gradual customer recapture and successful regulatory execution. The broader Tissue Reconstruction portfolio offers several recovery levers, yet second-quarter performance shows that the segment is not fully back to growth.
IART currently carries a Zacks Rank #3 (Hold). Its Value Score of B is the most supportive Style Score, while the Growth Score of C, VGM Score of C and Momentum Score of D are less favorable. Because Style Scores are designed to complement the Zacks Rank, the current mix supports a measured view of the 2027 catalyst rather than treating the SurgiMend relaunch as a stand-alone buy signal.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. IART has a Momentum Style Score of A, and shares are up 2.5% over the past four weeks.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.04 to $2.46 per share. IART also boasts an average earnings surprise of +19.8%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IART should be on investors' short list.
Key Takeaways Bassett Furniture, Aveanna Healthcare and Integra LifeSciences met breakout screening criteria.BSET, AVAH and IART trade near 52-week highs with recent price momentum and favorable technical signals.The screen favors stocks with strong rankings, controlled volatility and positive earnings growth outlooks. As August approaches, a relatively weak month for the stock market, investors should take a more active approach to stock selection, identifying potential breakout opportunities within defined trading ranges.
Going by this approach, a stock should be sold if it falls below the lower band, as this may signal further downside. Conversely, a move above the upper band indicates strengthening momentum, a potential breakout, and an opportunity to capture further gains.
Using this framework, Bassett Furniture Industries, Incorporated (BSET - Free Report) , Aveanna Healthcare Holdings Inc. (AVAH - Free Report) and Integra LifeSciences Holdings Corporation (IART - Free Report) stand out as potential breakout stocks ahead of August.
Spotting Breakout Stocks to Maximize Returns To pick a breakout stock, calculate support and resistance levels. A support level is the lower bound for stock movements, while a resistance level refers to the maximum price it trades at within a considerable period.
In other words, the demand for a stock is lowest at its support level, meaning most traders are willing to sell it. The majority of traders are willing to go long on the stock at the resistance level, indicating that they would like to add it to their portfolios. The key to identifying breakout stocks is to zero in on those on the verge of a breakout or those that have just broken above resistance.
Is the Stock Showing a Confirmed Breakout? The primary risk associated with such a strategy is that the decision to buy an apparent breakout candidate has been incorrectly timed. When a stock moves above the resistance level, it should be a highly prized commodity for traders. However, whether such a breakout is genuine is another matter altogether.
For a bona fide breakout, the stock’s earlier resistance barrier should become its new support level. This only happens if the established trading channel is tested by observing long-term price trends. The strength of the support and resistance levels can be ascertained only through such a study. Despite the risk of misidentification, correctly identifying such stocks can yield considerable returns, even at a price that may not seem attractive at first glance.
Research Wizard Screening Criteria: • Percentage price change over four weeks between 10% and 20% (Stocks showing considerable price increases but whose gains are not excessive)
• Current Price /52-Week High greater than or equal to 0.9 (Stocks trading 90% close to their 52-week highs.)
• Zacks Rank less than or equal to #2 (Only Strong Buy and Buy-rated stocks can get through.)
Regardless of market strength, stocks with a Zacks Rank of #1 (Strong Buy) or 2 (Buy) have a proven track record of outperforming the market. You can see the complete list of today’s Zacks #1 Rank stocks here.
• Beta for 60 months less than or equal to 2
(Stocks that move more than the broader market but within a reasonable limit.)
• Current price less than or equal to $20 (Stocks reasonably priced)
These criteria narrow the universe of more than 6,853 stocks to only 11.
Here are the top three stocks:
Bassett Furniture Industries Bassett Furniture Industries designs, manufactures, distributes and retails home furnishings across the United States. Bassett Furniture Industries has a Zacks Rank #1. BSET’s expected earnings growth rate for the current year is 18.7%.
Aveanna Healthcare Aveanna Healthcare provides pediatric and adult home healthcare services across the United States. Aveanna Healthcare has a Zacks Rank #2. AVAH’s expected earnings growth rate for the current year is 21.7%.
Integra LifeSciences Integra LifeSciences develops and markets surgical instruments and specialty medical products for neurosurgery, ENT and wound care. Integra LifeSciences has a Zacks Rank #2. IART’s expected earnings growth rate for the current year is 9.9%.
For the quarter ended June 2026, Integra LifeSciences (IART - Free Report) reported revenue of $418.76 million, up 0.8% over the same period last year. EPS came in at $0.56, compared to $0.45 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $419.6 million, representing a surprise of -0.2%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.48.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Revenue Growth: 0.7% compared to the 0% average estimate based on two analysts.Revenue- Tissue Technologies- Wound Reconstruction and Care: $81.31 million versus the two-analyst average estimate of $85.7 million. The reported number represents a year-over-year change of -4.1%.Revenue- Tissue Technologies- Total: $109.49 million versus $113.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change.Revenue- Codman Specialty Surgical- Total: $309.27 million versus $303.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change.Revenue- Tissue Technologies- Private Label: $28.19 million compared to the $27.5 million average estimate based on two analysts. The reported number represents a change of +4.8% year over year.View all Key Company Metrics for Integra here>>>
Shares of Integra have returned +10% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
3 Undervalued Midcaps Ready to PopIntegra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company’s guidance range.
Get Integra LifeSciences alerts:
Chairman, President and Chief Executive Officer Stuart Essig said the company delivered on its commitments during the quarter and continued to strengthen its operational foundation. “We are operating with greater consistency and strengthening our foundation for long-term growth,” Essig said.
The company reaffirmed its full-year organic revenue growth outlook of 0.8% to 3.3% and its adjusted EPS guidance of $2.40 to $2.50. It updated its reported revenue outlook to $1.654 billion to $1.695 billion, reflecting the impact of foreign exchange rates and a stronger U.S. dollar.
Margins Improve as Tariffs Aid Quarterly EPS Chief Financial Officer Lea Knight said revenue delivery and transformation savings were in line with expectations, while stronger operational execution helped drive earnings to the high end of the company’s guidance range. Integra also benefited from approximately $0.05 per share of tariff favorability relative to its May outlook.
Gross margin reached 61.3%, compared with 60.7% in the prior-year period, reflecting manufacturing efficiencies and lower remediation spending. Adjusted EBITDA margin expanded 160 basis points to 18.7%.
Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share.
“We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds,” Knight said.
Integra expects third-quarter revenue of $410 million to $425 million, representing organic growth of 1.9% to 5.7%, and adjusted EPS of $0.53 to $0.61.
Specialty Surgery Growth Led by Neurosurgery Specialty Surgery revenue totaled $309.3 million, increasing 1.7% on a reported basis and 1.6% organically. Global Neurosurgery grew 1.9% organically, supported by demand for Certas Plus, CUSA and Bactiseal as supply fulfillment improved.
Capital equipment sales declined about 1%, as double-digit CUSA growth was offset by lower sales of smaller-ticket capital equipment. Knight said Integra continues to view the hospital capital environment positively and expects capital equipment growth for the full year.
Instruments revenue grew low single digits, benefiting partly from order timing compared with the first quarter. ENT revenue declined by low single digits, as growth in MicroFrance ENT instruments was more than offset by continuing pressure in sinus balloons. The company expects ENT revenue to decline for the full year and is focused on innovation in navigated systems and Eustachian-tube products to support longer-term growth.
Essig said the company’s improved supply position allows the commercial organization to be more proactive. Its new commercial structure is designed to increase accountability, accelerate decision-making and expand enterprise contracting. Integra plans to leverage relationships with group purchasing organizations and integrated delivery networks built through its neurosurgery and specialty surgery businesses to support Tissue Reconstruction and ENT products.
Tissue Reconstruction Faces Comparisons, Prepares SurgiMend Relaunch Tissue Reconstruction revenue was $109.5 million, down 1.9% on a reported basis and 2% organically. Wound Reconstruction was approximately flat for the first half of 2026 versus the prior year, a result management said remains consistent with its full-year expectations.
Integra Skin increased sequentially from the first quarter but declined from the prior-year period, when revenue benefited from a significant clearance of product backorders. MicroMatrix also declined, which Knight attributed to increased competition from new powder-form product entrants.
PriMatrix continued to gain traction following its relaunch. Essig said that about nine months after returning to the market, PriMatrix revenue had recovered to slightly more than 50% of pre-recall levels. He said the company has seen customer re-engagement and identified new opportunities while working to regain former customers.
Integra has restarted manufacturing at its Braintree facility and is building inventory for a controlled fourth-quarter relaunch of SurgiMend 510(k) product. The company expects no meaningful SurgiMend contribution in 2026, but Essig said it expects share recapture to build across multiple quarters. He described a modest initial recovery, referencing approximately 50% of SurgiMend’s historical $40 million performance.
The company is also pursuing PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction. Essig said SurgiMend’s clinical safety and efficacy review has been completed and its PMA is pending a successful pre-approval inspection at Braintree. The company expects SurgiMend approval earlier in 2027 and DuraSorb approval later that year, subject to FDA timing and inspections.
Separately, Essig said Integra continues work to return MediHoney to market in 2027, though no contribution is included in 2026 guidance.
Cash Flow and Deleveraging Remain Priorities Operating cash flow was $22.8 million in the quarter, compared with $8.9 million a year earlier, despite including an $11 million final milestone payment related to the Sia acquisition. Free cash flow was $10.5 million, representing a 24% conversion rate.
As of June 30, Integra had net debt of $1.6 billion and a consolidated total leverage ratio of 4.1 times, down from 4.5 times at the end of 2025. Total liquidity was approximately $496 million, including $274 million in cash and short-term investments.
The company expects about a $150 million improvement in operating cash flow for 2026, driven by EBITDA growth, working-capital efficiency and lower cash expenditures related to EU MDR compliance and Braintree startup costs. Management said reducing leverage and repaying debt remain its top capital allocation priorities, with an objective of approaching the upper end of its 2.5-times to 3.5-times target leverage range by year-end.
Knight also said flooding in the Cincinnati area recently disrupted operations at a manufacturing site. Based on available distribution-center inventory, secondary supply sources and insurance coverage, Integra does not expect the event to materially affect its 2026 revenue or EPS guidance.
About Integra LifeSciences (NASDAQ:IART)Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Integra LifeSciences Right Now?Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Integra LifeSciences (IART - Free Report) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this medical device maker would post earnings of $0.41 per share when it actually produced earnings of $0.54, delivering a surprise of +31.71%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $418.76 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.2%. This compares to year-ago revenues of $415.61 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Integra shares have added about 59.1% since the beginning of the year versus the S&P 500's gain of 8.5%.
What's Next for Integra?While Integra has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Integra was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.58 on $415.81 million in revenues for the coming quarter and $2.45 on $1.67 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Sight Sciences, Inc. (SGHT - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.
This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +34.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Sight Sciences, Inc.'s revenues are expected to be $21.75 million, up 11.2% from the year-ago quarter.
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
Second Quarter 2026 Highlights
Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year. Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates.The Company is reaffirming its 2026 full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50.The Company initiated production at its Braintree manufacturing facility and remains on track for the planned fourth-quarter relaunch of SurgiMend®.
"Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences.
"At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value."
Second Quarter 2026 Consolidated Performance
Total reported revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
The Company reported GAAP gross margin of 52.5%, compared to 50.4% in the second quarter of 2025. Adjusted gross margin was 61.3%, compared to 60.7% in the prior year.
Adjusted EBITDA for the second quarter of 2026 was $78.4 million, or 18.7% of revenue, compared to $71.2 million, or 17.1% of revenue, in the prior year.
The Company reported GAAP net income of $4.5 million, or $0.06 per diluted share, in the second quarter of 2026, compared to GAAP net loss of $(484.1) million, or $(6.31) per diluted share, in the prior year.
Adjusted net income for the second quarter of 2026 was $43.7 million, or $0.56 per diluted share, compared to $34.4 million, or $0.45 per diluted share, in the prior year.
Second Quarter 2026 Segment Performance
Specialty Surgery (~70% of Revenues)
Total revenues were $309.3 million, representing reported growth of 1.7% and an organic growth of 1.6% compared to the second quarter of 2025.
Sales in Neuro increased 1.9% on an organic basis primarily driven by growth in Certas® Plus, Bactiseal® and CUSA®.Sales in Instruments grew 3.2% on an organic basis. ENT sales declined (1.9%) as MicroFrance® ENT instrument growth was offset by declines in other products.
Tissue Reconstruction (~30% of Revenues)
Total revenues were $109.5 million, representing reported and organic declines of (1.9)% and (2.0)% respectively compared to the second quarter of 2025. Key drivers for the quarter include:
Mid-single digit decline in wound reconstruction, driven by strong growth in DuraSorb® and the relaunch of PriMatrix®, offset by declines in MicroMatrix® and Integra Skin. Integra Skin faced a prior year comparison that included the clearance of back orders in the second quarter of 2025.Sales in private label grew 4.7%. Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of $22.8 million in the quarter. Net debt at the end of the quarter was $1.6 billion, and the consolidated total leverage ratio was 4.1x.
As of the end of the quarter, the Company had total liquidity of approximately $496 million, including $274.1 million in cash plus short-term investments and the remainder available under its revolving credit facility.
2026 Revenue and Adjusted Earnings Per Share Guidance
For the third quarter of 2026, the Company expects reported revenues in the range of $410 million to $425 million, representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. The Company expects adjusted EPS in the range of $0.53 to $0.61 per share.
The Company is updating its reported revenue outlook from a range of $1.662 billion to $1.702 billion to a range of $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates. For the full year 2026, the Company is reaffirming its organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50. The adjusted EPS outlook reflects updated tariff assumptions, a higher interest rate environment, and potential debt refinancing actions.
The Company's organic sales growth guidance for the third quarter and full year excludes the impact of acquisitions, divestitures, and foreign currency.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, July 29, 2026, to discuss second quarter 2026 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the company's website following the call.
About Integra
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company’s expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company's Braintree facility and the the relaunch of SurgiMend in the fourth quarter of 2026. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company’s suppliers, vendors and customers and on the Company’s business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the failure of the company’s suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company’s products in these markets; the Company’s ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the "Braintree transition"); (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to Braintree transition; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
The Company has included reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended June 30, 2026 and 2025. The Company has included a reconciliation of GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025.
The Company is providing forward-looking guidance regarding organic revenue and adjusted earnings per diluted share but is not providing reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736 [email protected]
Three Months Ended June 30, 2026 2025 Total revenue, net$418,761 $415,605 Costs and expenses: Cost of goods sold 199,017 206,273 Research and development 24,253 26,997 Selling, general and administrative 172,436 179,890 Intangible asset amortization 3,770 3,754 Goodwill impairment charge — 511,365 Total costs and expenses 399,476 928,279 Operating income (loss) 19,285 (512,674)Interest income 4,267 4,710 Interest expense (22,994) (21,042)Other income (expense), net 4,186 (1,946)Income (loss) before income taxes 4,744 (530,952)Provision (benefit) for income taxes 262 (46,879)Net income (loss)$4,482 $(484,073) Net income (loss) per share Diluted$0.06 $(6.31) Weighted average common shares outstanding 78,168 76,695 The following table presents revenues disaggregated by the major sources for the three months ended June 30, 2026 and 2025 (amounts in thousands):
Three Months Ended June 30, 2026 2025ChangeNeurosurgery$213,264 $208,9922.0%Instruments 54,806 53,0803.3%ENT 41,199 41,886(1.6)%Total Specialty Surgical 309,269 303,9581.7% Wound Reconstruction Solutions 81,305 84,747(4.1)%Private Label 28,187 26,9004.8%Total Tissue Reconstruction 109,492 111,647(1.9)%Total Reported Revenues$418,761 $415,6050.8% Impact of changes in currency exchange rates (440) — Total organic revenues(1)$418,316 $415,6050.7% (1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2026
ItemTotal
AmountCOGS(a)SG&A(b)R&D(c)Amort (d)OI&E(e)Tax(f)Acquisition, divestiture and integration-related charges2,383 351,503 599—247— Structural Optimization charges7,513 3,3664,094 53——— EU Medical Device Regulation charges2,439 2181,017 1,205——— Braintree Transition9,918 10,309(398) 7——— Intangible asset amortization expense26,969 23,198— —3,770—— Estimated income tax impact from above adjustments and other items(9,992) —— ———(9,992) Depreciation expense10,154 —— ———— a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2025
ItemTotal
AmountCOGS(a)SG&A(b)R&D(c)Amort (d)OI&E(e)Tax(f)Acquisition, divestiture and integration-related charges4,963 —4,258270 —435— Structural Optimization charges5,944 5,1871,073(316) ——— EU Medical Device Regulation charges10,681 1,1424,2005,338 ——— Braintree Transition13,630 13,53298— ——— Intangible asset amortization expense26,795 23,041—— 3,754—— Estimated income tax impact from above adjustments and other items(54,940) ——— ——(54,940) Depreciation expense10,955 ——— ——— a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands) Three Months Ended June 30, 2026 2025 GAAP net income (loss)$4,482 $(484,073)Non-GAAP adjustments: Goodwill impairment charges — 511,365 Depreciation and intangible asset amortization expense 37,123 37,750 Other (income) expense, net (4,186) 1,511 Interest expense, net 18,480 16,332 Income tax expense 262 (46,879)Structural optimization charges 7,513 5,944 EU Medical Device Regulation charges 2,439 10,681 Braintree Transition 9,918 13,630 Acquisition, divestiture and integration-related charges 2,383 4,963 Total of non-GAAP adjustments 73,932 555,297 Adjusted EBITDA$78,414 $71,224 RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
(In thousands, except per share amounts) Three Months Ended June 30, 2026 2025 GAAP net income (loss)$4,482 $(484,073)Non-GAAP adjustments: Structural optimization charges 7,513 5,944 Acquisition, divestiture and integration-related charges 2,383 4,963 EU Medical Device Regulation charges 2,439 10,681 Braintree Transition 9,918 13,630 Goodwill impairment charges — 511,365 Intangible asset amortization expense 26,969 26,795 Estimated income tax impact from adjustments and other items (9,992) (54,940)Total of non-GAAP adjustments 39,230 518,438 Adjusted net income$43,712 $34,365 Adjusted diluted net income per share$0.56 $0.45 Weighted average common shares outstanding for diluted net income per share 78,168 76,769 CONDENSED BALANCE SHEET DATA
(UNAUDITED)
(In thousands)
June 30,
2026 December 31,
2025 Short term investments$59,669 $28,693Cash and cash equivalents 214,415 235,048Trade accounts receivable, net 267,188 278,849Inventories, net 492,005 492,735 Current and long-term borrowing under senior credit facility 1,779,699 1,768,306Borrowings under securitization facility 92,600 87,800Convertible securities — — Stockholders' equity$1,043,377 $1,043,463 CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED)
(In thousands)
Six Months Ended June 30, 2026 2025 Net cash (used) provided by operating activities$32,605 $(2,338)Net cash used in investing activities (58,131) (57,568)Net cash provided by financing activities 7,479 14,238 Effect of exchange rate changes on cash and cash equivalents (2,586) 17,207 Net decrease in cash and cash equivalents$(20,633) $(28,461) RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands) Three Months Ended June 30, 2026 2025 Net cash provided by operating activities$22,802 $8,919 Purchases of property and equipment (12,307) (20,146)Free cash flow$10,495 $(11,227) Adjusted net income(1)$43,712 $34,365 Adjusted free cash flow conversion 24.0%(32.7)% Twelve Months Ended June 30, 2026 2025 Net cash provided by operating activities$85,327 $70,888 Purchases of property and equipment (59,525) (108,311)Free cash flow$25,802 $(37,423) Adjusted net income(1)$190,633 $171,011 Adjusted free cash flow conversion 13.5%(21.9)% (1) Adjusted net income for quarters ended June 30, 2026 and 2025 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION
(UNAUDITED) (In thousands) June 30,
2026December 31,
2025Short-term borrowings under senior credit facility$43,594 $38,750 Long-term borrowings under senior credit facility 1,736,105 1,729,556 Borrowings under securitization facility 92,600 87,800 Convertible securities — — Deferred financing costs netted in the above 2,489 3,257 Short term investments (59,669) (28,693)Cash & Cash Equivalents (214,415) (235,048)Net Debt$1,600,704 $1,595,622 RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP GROSS PROFIT TO MEASURES OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(UNAUDITED)
(In thousands, except percentages) Three Months Ended June 30, 2026 2025 Total revenues, net$418,761 $415,605 Cost of goods sold 199,017 206,273 Reported Gross Profit 219,744 209,332 Structural optimization charges 3,366 5,187 Acquisition, divestiture and integration-related charges 35 — Braintree Transition 10,309 13,532 EU Medical Device Regulation 218 1,142 Intangible asset amortization expense 23,199 23,041 Adjusted Gross Profit$256,871 $252,234 Total Revenues$418,761 $415,605 Adjusted Gross Margin 61.3% 60.7%
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 7.98; value investors should take notice.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.03 to $2.45 per share. IART also boasts an average earnings surprise of +16.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IART should be on investors' short list.
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (âIntegraâ) on beha
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/cases/integra-lifesciences/ Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023 (the “Wrongdoing Period”.
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART - Free Report) and SONOVA HOLDING (SONVY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Right now, Integra LifeSciences is sporting a Zacks Rank of #2 (Buy), while SONOVA HOLDING has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that IART is likely seeing its earnings outlook improve to a greater extent. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
IART currently has a forward P/E ratio of 7.77, while SONVY has a forward P/E of 17.84. We also note that IART has a PEG ratio of 1.32. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SONVY currently has a PEG ratio of 3.63.
Another notable valuation metric for IART is its P/B ratio of 1.42. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SONVY has a P/B of 4.46.
Based on these metrics and many more, IART holds a Value grade of B, while SONVY has a Value grade of C.
IART is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that IART is likely the superior value option right now.
Shares of Integra LifeSciences (IART - Free Report) have been strong performers lately, with the stock up 9.2% over the past month. The stock hit a new 52-week high of $19.13 in the previous session. Integra has gained 51.2% since the start of the year compared to the -0.7% move for the Zacks Medical sector and the -14.2% return for the Zacks Medical - Instruments industry.
What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 5, 2026, Integra reported EPS of $0.54 versus consensus estimate of $0.41 while it beat the consensus revenue estimate by 2.74%.
For the current fiscal year, Integra is expected to post earnings of $2.45 per share on $1.67 in revenues. This represents a 9.87% change in EPS on a 2.43% change in revenues. For the next fiscal year, the company is expected to earn $2.59 per share on $1.73 in revenues. This represents a year-over-year change of 5.82% and 3.27%, respectively.
Valuation MetricsThough Integra has recently hit a 52-week high, what is next for Integra? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Integra has a Value Score of B. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 7.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 25.5X. On a trailing cash flow basis, the stock currently trades at 4.4X versus its peer group's average of 13.6X. Additionally, the stock has a PEG ratio of 1.3. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Integra currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integra fits the bill. Thus, it seems as though Integra shares could have potential in the weeks and months to come.
How Does IART Stack Up to the Competition?Shares of IART have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Alcon (ALC - Free Report) . ALC has a Zacks Rank of #2 (Buy) and a Value Score of B, a Growth Score of C, and a Momentum Score of B.
Earnings were strong last quarter. Alcon beat our consensus estimate by 6.25%, and for the current fiscal year, ALC is expected to post earnings of $3.50 per share on revenue of $11.08 billion.
Shares of Alcon have gained 6.8% over the past month, and currently trade at a forward P/E of 19.55X and a P/CF of 12.49X.
The Medical - Instruments industry may rank in the bottom 71% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for IART and ALC, even beyond their own solid fundamental situation.
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Key Takeaways IART gained 52.1% in a year, driven by growth across Specialty Surgery and Tissue Reconstruction. IART reported Q1 2026 EPS above guidance as margins benefited from favorable mix and transformation savings. IART faces risks from high debt, trade uncertainty and the FDA warning letter despite ongoing improvements. Integra LifeSciences’ (IART - Free Report) shares have surged 52.1% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 5.1% decline and the S&P 500 composite’s 23.3% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.
Based in Plainsboro, NJ, Integra develops, manufactures and markets surgical implants and medical instruments. The company’s Specialty Surgery segment consists of neurosurgery, instruments and ENT surgical solutions, augmented by the 2024 acquisition of Acclarent. Its Tissue Reconstruction segment focuses on wound reconstruction, surgical reconstruction and peripheral nerve repair.
Key Catalysts for IART’s GrowthIntegra’s share price is trending upward, prompted by strong prospects in both the reporting segments. In first-quarter 2026, Specialty Surgery revenues totaled $283.1 million, with global neurosurgery sales up 1.9% organically on demand for Certas Plus, CUSA and BactiSeal, as supply reliability and fulfillment improved.
Capital equipment sales increased in the low single digits, supported by continued strength in the capital funnel, including double-digit growth in CUSA and CereLink. Acclarent remains a key part of the ENT platform by expanding the portfolio across sinus and eustachian tube balloon technologies and navigation, which can broaden addressable markets over time.
Tissue Reconstruction revenues grew 6.4% organically, reflecting double-digit growth in Integra Skin, mid-double-digit growth in DuraSorb and the PriMatrix launch. Private label sales grew 7.1% on a favorable prior-year comparison.
The investors are also impressed with the company’s multi-year work on quality, compliance, capacity and transformation, which remains central to restoring predictable execution. In line with this, first-quarter adjusted EPS was $0.54, above the high end of guidance, supported by favorable mix and transformation savings, with adjusted gross margin of 64.1% and adjusted EBITDA margin of 19.4%. Integra continues to advance the PMA strategy for both SurgiMend and DuraSorb for implant-based breast reconstruction.
Image Source: Zacks Investment Research
Factors That May Offset IART’s GainsIntegra’s position looks quite tight from the liquidity point of view, having ended the first quarter of 2026 with net debt of $1.60 billion and cash and cash equivalents of $236.8 million. The company has $39 million in current debt and $1.87 billion in total debt on its balance sheet.
The company flagged continuing geopolitical and trade uncertainty, which can raise supplier costs and affect customer purchasing patterns. The FDA warning letter issued in December 2024 continues to frame execution risk across multiple facilities. While the company has adopted a risk-based approach and continues to advance its transformation and operational resiliency initiatives, execution delays could still lead to disruption, higher costs and slower product flow.
A Glance at IART’s EstimatesIn the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved north to $2.45.
Revenues are projected to grow 2.4% to $1.67 billion in 2026, while the same for 2027 is expected to reach $1.73 billion (up 3.3%).
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Alcon (ALC - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alcon, carrying a Zacks Rank #2 at present, has an earnings yield of 5.1% against the industry’s negative 2.8% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. ALC’s earnings topped estimates in three of the trailing four quarters and missed in one, the average surprise being 3.7%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, investors find themselves loaded up on expensive shares with limited to no upside or even a downside. So, going all-in on momentum could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Integra LifeSciences (IART - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 1.2% over the past four weeks positions the stock of this medical device maker well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. IART meets this criterion too, as the stock gained 56.9% over the past 12 weeks.
Moreover, the momentum for IART is fast paced, as the stock currently has a beta of 1.22. This indicates that the stock moves 22% higher than the market in either direction.
Given this price performance, it is no surprise that IART has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped IART earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, IART is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. IART is currently trading at 0.82 times its sales. In other words, investors need to pay only 82 cents for each dollar of sales.
So, IART appears to have plenty of room to run, and that too at a fast pace.
In addition to IART, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 7.07; value investors should take notice.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $2.45 per share. IART also boasts an average earnings surprise of +16.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IART should be on investors' short list.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Kirlew will lead Integra’s global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. July 02, 2026 08:30 ET | Source: Integra LifeSciences Holdings Corporation
PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.
Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.
"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."
Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.
Prior to joining Integra, Kirlew held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.
Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.
On June 30, 2026, Integra Lifesciences Holdings Corp (IART) shares fell 4.2% to $17.98, amid a 52-week trading range of $8.70 to $18.92. This decline comes desp
Integra LifeSciences specializes in neuro-related surgical devices and regenerative tissue technologies. The tissue reconstruction segment, featuring collagen-based products like Integra Skin and PriMatrix, is positioned as IART's primary future earnings driver. IART suffered significant earnings declines and a 75% share price drop due to FDA-related product recalls and operational lapses at its Boston facility.
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Integra LifeSciences (IART - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 16.4%, the stock of this medical device maker is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. IART meets this criterion too, as the stock gained 91.1% over the past 12 weeks.
Moreover, the momentum for IART is fast paced, as the stock currently has a beta of 1.24. This indicates that the stock moves 24% higher than the market in either direction.
Given this price performance, it is no surprise that IART has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped IART earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, IART is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. IART is currently trading at 0.83 times its sales. In other words, investors need to pay only 83 cents for each dollar of sales.
So, IART appears to have plenty of room to run, and that too at a fast pace.
In addition to IART, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. IART has a Momentum Style Score of B, and shares are up 16.4% over the past four weeks.
For fiscal 2026, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.13 to $2.45 per share. IART boasts an average earnings surprise of +16.8%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IART should be on investors' short list.
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization.
Key Takeaways MITT, SVM and IART are highlighted as stocks to consider after recent broker rating upgrades.MITT's 2026 earnings are expected to rise 26.7%, with broker ratings up 14.3% in four weeks.SVM and IART have projected earnings growth of 30.4% and 9.9%, respectively, plus recent broker rating gains. U.S. equities have shown resilience year to date, though gains have been highly uneven. After recovering from early volatility, markets have moved higher as strong corporate earnings, AI-driven optimism and a still-supportive economy have helped offset broader macro concerns and hawkish Federal Reserve. Investor sentiment has continued to shift with swings in Treasury yields, oil-price volatility, geopolitical risks (particularly Middle East tensions) and evolving tariff policies.
As such, it is not easy for retail investors to select stocks for generating robust returns over time. One way to cut short this task is to follow brokers’ recommendations. In this regard, stocks such as TPG Mortgage Investment Trust, Inc. (MITT - Free Report) , Silvercorp Metals Inc. (SVM - Free Report) and Integra LifeSciences Holdings Corporation (IART - Free Report) are worth considering.
Broker recommendations are typically based on a comprehensive research process that combines direct access to company management, detailed analysis of public disclosures, participation in earnings calls, channel checks, and broader industry. This allows analysts to assess a company’s fundamentals within the context of macroeconomic trends, industry dynamics, competitive positioning, and peer performance, rather than evaluating the business in isolation.
A broker upgrade often reflects a meaningful improvement in an analyst’s outlook for a company. Such a revision may be driven by several factors that may not yet be fully incorporated into consensus estimates or market valuations. Hence, an upgrade can signal a potential inflection point in earnings expectations and investor sentiment.
However, broker upgrades should not be viewed as standalone investment signals. They are most effective when considered alongside other fundamental and valuation factors. As such, broker recommendations should be used as one component of a broader, well-rounded investment decision-making framework.
Selecting the Winning StrategyWe have a screening strategy that may help you identify potential winners.
Broker Rating Upgrades (Four Weeks) of 1% or More: The screen selects stocks that have witnessed broker rating upgrades of 1% or more over the past four weeks.
Current Price Greater Than $5: The stocks must trade above $5.
Average 20-Day Volume Greater Than 100,000: A large trading volume guarantees that the stock is easily tradable.
Zacks Rank Equal to #1 (Strong Buy) or 2 (Buy): Despite good or bad market conditions, stocks with a Zacks Rank #1 or 2 have a proven record of success. You can see the complete list of today’s Zacks #1 Rank stocks here.
VGM Score of A or B: Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.
3 Stocks With Upgraded Broker Ratings to BuyNew York-based TPG Mortgage is a residential mortgage real estate investment trust. MITT’s investment portfolio comprises residential investments, non-agency residential mortgage-backed securities, commercial loans and commercial mortgage-backed securities.
MITT’s 2026 earnings are expected to increase 26.7% year over year. TPG Mortgage, which currently carries a Zacks Rank #2, has witnessed a 14.3% upward revision in broker ratings over the past four weeks.
Silvercorp Metals, based in Canada, acquires, explores, develops and mines mineral properties in China. SVM explores for copper, silver, gold, lead and zinc metals.
Silvercorp Metals’ fiscal 2027 earnings are projected to jump 30.4% on a year-over-year basis. SVM, sporting a Zacks Rank #1 at present, has witnessed a 16.7% upward revision in broker ratings over the past four weeks.
Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the leading names in regenerative medicine. IART develops, manufactures and markets surgical implants and medical instruments.
Integra LifeSciences’ 2026 earnings are expected to rise 9.9% year over year. IART, which currently carries a Zacks Rank #2, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.
Have you been paying attention to shares of Integra LifeSciences (IART - Free Report) ? Shares have been on the move with the stock up 23.7% over the past month. The stock hit a new 52-week high of $18.19 in the previous session. Integra has gained 40.6% since the start of the year compared to the -4.2% move for the Zacks Medical sector and the -16.9% return for the Zacks Medical - Instruments industry.
What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 5, 2026, Integra reported EPS of $0.54 versus consensus estimate of $0.41 while it beat the consensus revenue estimate by 2.74%.
For the current fiscal year, Integra is expected to post earnings of $2.42 per share on $1.67 in revenues. This represents a 8.52% change in EPS on a 2.24% change in revenues. For the next fiscal year, the company is expected to earn $2.57 per share on $1.73 in revenues. This represents a year-over-year change of 6.3% and 3.27%, respectively.
Valuation MetricsWhile Integra has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Integra has a Value Score of B. The stock's Growth and Momentum Scores are B and F, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 7.2X current fiscal year EPS estimates, which is not in-line with the peer industry average of 23.1X. On a trailing cash flow basis, the stock currently trades at 4.1X versus its peer group's average of 13.3X. Additionally, the stock has a PEG ratio of 1.22. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Integra currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integra passes the test. Thus, it seems as though Integra shares could have potential in the weeks and months to come.
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART - Free Report) and SONOVA HOLDING (SONVY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Integra LifeSciences and SONOVA HOLDING are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that IART likely has seen a stronger improvement to its earnings outlook than SONVY has recently. But this is just one piece of the puzzle for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
IART currently has a forward P/E ratio of 7.18, while SONVY has a forward P/E of 17.51. We also note that IART has a PEG ratio of 1.22. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SONVY currently has a PEG ratio of 3.57.
Another notable valuation metric for IART is its P/B ratio of 1.31. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, SONVY has a P/B of 4.38.
These are just a few of the metrics contributing to IART's Value grade of B and SONVY's Value grade of C.
IART sticks out from SONVY in both our Zacks Rank and Style Scores models, so value investors will likely feel that IART is the better option right now.
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED - Free Report) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis medical device company is expected to post quarterly earnings of $0.92 per share in its upcoming report, which represents a year-over-year change of +35.3%.
Revenues are expected to be $730.32 million, up 22.1% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Globus Medical?For Globus Medical, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.91%.
On the other hand, the stock currently carries a Zacks Rank of #1.
So, this combination makes it difficult to conclusively predict that Globus Medical will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Globus Medical would post earnings of $1.06 per share when it actually produced earnings of $1.28, delivering a surprise of +20.75%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Globus Medical doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Instruments industry, Integra LifeSciences (IART - Free Report) , is soon expected to post earnings of $0.41 per share for the quarter ended March 2026. This estimate indicates no change from the year-ago quarter. Revenues for the quarter are expected to be $381.46 million, down 0.3% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Integra has remained unchanged. Nevertheless, the company now has an Earnings ESP of +0.82%, reflecting a higher Most Accurate Estimate.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Integra will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Stuart Essig Appointed as Integra’s Next President and Chief Executive Officer
Michael McBreen Appointed Chief Commercial Officer
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra’s Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities.
The Company also announced that Michael McBreen, currently executive vice president, president, Codman Specialty Surgical, has been appointed chief commercial officer.
Mr. Essig brings more than thirty years of experience in the medical technology and healthcare industries and has deep familiarity with Integra, having served as chairman of the board since June 2012 and as a director since 1997. He previously served as Integra’s chief executive officer from 1997 through early 2012, and as its President from 1997 until 2010. Over the past two years, Mr. Essig has been actively engaged in the business through his executive chairman role, with direct involvement in key company priorities as well as operational and quality matters.
"Stuart brings unmatched knowledge of Integra, its businesses, and its people," said Barbara Hill, presiding director. "He combines deep institutional knowledge with a clear understanding of the work underway across the organization. We have full confidence in his leadership as Integra accelerates execution, strengthens customer and commercial focus, and builds on the important progress already underway across its priorities for 2026. The Board believes this is the right leadership step for the Company’s next phase, and as such, this is not an interim role, and we do not intend to initiate a CEO search."
"I am honored to once again serve as Integra’s president and CEO," said Mr. Essig. "I return with a clear mandate from the Board and a long-term commitment to lead the Company through its next chapter. In my role as executive chairman, I have seen firsthand the strength of our team and the meaningful progress underway across our priorities, particularly in quality, compliance, operational resilience, and the transformation of the organization.”
Mr. Essig continued, " As I step back into the CEO role, my focus will be on accelerating execution, strengthening our customer and commercial focus, and reinforcing a culture and operating discipline that will drive sustained performance and deliver long-term shareholder value. I know this company, I understand what it takes to run it, and I am deeply committed to leading Integra forward."
Mr. Essig added, "I also want to thank Mojdeh for her numerous contributions to the company and for the meaningful progress made during her tenure. Under her leadership, the Company advanced several important strategic and operational priorities, including enterprise-wide portfolio and program prioritization, risk-based approach to quality remediation work, operational resiliency improvements, and the more recent transformation and business process optimization efforts. These initiatives are progressing well, and we remain fully committed to them.”
As part of this leadership update, the Company also announced that Michael McBreen has been appointed chief commercial officer. In this newly created role, Mr. McBreen will help drive the next phase of Integra’s performance by further elevating the commercial organization and ensuring that customer and market-facing priorities are central to how the Company operates and makes decisions. Both divisions and the entire global commercial structure will report to Mr. McBreen, with his appointment intended to strengthen revenue growth, customer outcomes, and execution across the business.
“Mike is exceptionally well-suited for this role with deep commercial relationships," Mr. Essig said. "He brings more than thirty years of commercial experience in the medical technology industry, and his appointment is an important part of how we move forward. This is a strategic leadership step that will help sharpen execution, strengthen our connection to our customers and markets, and support stronger performance across the Company. Integra intends to lead this next chapter with urgency, transparency, and a clear focus on execution."
Mr. Essig will address the leadership transition during Integra’s first quarter 2026 financial results conference call, which will take place this morning at 8:30 a.m. Eastern time. A live webcast will be available on the Investors section of the Company’s website.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery, tissue reconstruction, and specialized surgical solutions that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver life-saving care. For the latest news and information, visit www.integralife.com.
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026.
First Quarter 2026 Highlights
First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings per share guidance from a range of $2.30 to $2.40 to a range of $2.40 to $2.50. As noted in a separate press release issued this morning, Stuart Essig has been appointed as Integra’s next President and Chief Executive Officer and Michael McBreen has been promoted to Chief Commercial Officer. “Our first-quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold,” said Stuart Essig, chairman and chief executive officer.
“During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix® and Durepair®. We made meaningful progress at our state-of-the-art Braintree manufacturing facility and remain on track to begin production of SurgiMend® by the end of June to support a fourth quarter launch. Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full-year commitments to our customers, patients, and shareholders."
First Quarter 2026 Consolidated Performance
Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year.
The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year.
Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year.
The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per diluted share, in the first quarter of 2026, compared to GAAP net loss of $(25.3) million, or $(0.33) per diluted share, in the prior year.
Adjusted net income for the first quarter of 2026 was $41.6 million, or $0.54 per diluted share, compared to $31.7 million, or $0.41 per diluted share, in the prior year.
First Quarter 2026 Segment Performance
The Company is changing its segment names, with Codman Specialty Surgical renamed Specialty Surgery and Tissue Technologies renamed Tissue Reconstruction. Product brand names remain unchanged. The change to segment names has no financial impact.
Specialty Surgery (~70% of Revenues)
Total revenues were $283.1 million, representing reported growth of 0.9% and an organic decline of (0.6)% compared to the first quarter of 2025.
Sales in Neuro increased 1.9% on an organic basis primarily driven by growth in Certas® Plus, CUSA® and Bactiseal®Sales in Instruments declined (7.7%) on an organic basis due to order timingENT sales declined (3.8)% as growth in MicroFrance® ENT instruments was offset by declines in other products Tissue Reconstruction (~30% of Revenues)
Total revenues were $108.8 million, representing reported growth of 6.7% and organic growth of 6.4% compared to the first quarter of 2025. Key drivers for the quarter include:
Mid-single digit growth in wound reconstruction, driven by double-digit growth in Integra Skin, DuraSorb® and the relaunch of PriMatrix®, partially offset by MediHoney®Sales in private label grew 7.1% primarily due to a favorable prior year comparable Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of $9.8 million in the quarter. Net debt at the end of the quarter was $1.6 billion, and the consolidated total leverage ratio was 4.1x.
As of the end of the quarter, the Company had total liquidity of approximately $488 million, including $265.5 million in cash plus short-term investments and the remainder available under its revolving credit facility.
2026 Revenue and Adjusted Earnings Per Share Guidance
For the second quarter 2026, the Company expects reported revenues in the range of $410 million to $425 million, representing reported growth of (1.3%) to 2.3% and organic growth of (1.5%) to 2.1%. The Company expects adjusted EPS in a range of $0.44 to $0.52 per share.
For the full year 2026, the Company is reiterating its revenue guidance range to $1.662 billion to $1.702 billion. The revenue range represents reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3%. The Company is updating its expected adjusted EPS to a range of $2.40 to $2.50 per share reflecting the first quarter benefits from the IEEPA tariffs.
The Company’s organic sales growth guidance for the second quarter and the full year excludes acquisitions and divestitures, as well as the effects of foreign currency.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Thursday, May 5, 2026, to discuss first quarter 2026 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the company website following the call.
About Integra
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company’s expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company’s compliance master plan to improve the Company's quality systems. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and
other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company’s suppliers, vendors and customers and on the Company’s business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the failure of the company’s suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company’s products in these markets; the Company’s ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the manufacturing stoppage and voluntary global recall of all products manufactured at the Company’s Boston, Massachusetts facility and distributed between March 1, 2018 and May 22, 2023, as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2023 (the “recall”) and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility; (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to the recall and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
Reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, GAAP total debt to net debt, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended March 31, 2026 and 2025.
The Company is providing forward-looking guidance regarding organic revenue and adjusted earnings per diluted share but is not providing reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736 [email protected]
INTEGRA LIFESCIENCES HOLDINGS CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except per share amounts)
Three Months Ended March 31, 2026 2025 Total revenue, net$391,918 $382,653 Costs and expenses: Cost of goods sold 174,936 188,221 Research and development 23,501 24,728 Selling, general and administrative 178,235 181,497 Intangible asset amortization 3,776 3,704 Total costs and expenses 380,448 398,150 Operating income (loss) 11,470 (15,497)Interest income 4,106 4,420 Interest expense (22,465) (18,815)Other income (expense), net 4,480 (144)Loss before income taxes (2,409) (30,036)Provision for income taxes 2,208 (4,743)Net loss$(4,617) $(25,293) Net loss per share Diluted$(0.06) $(0.33) Weighted average common shares outstanding 76,951 76,463 The following table presents revenues disaggregated by the major sources for the three months ended March 31, 2026 and 2025 (amounts in thousands):
Three Months Ended March 31, 2026 2025ChangeNeurosurgery$198,195 $190,9123.8%Instruments 47,233 50,950(7.3)%ENT 37,707 38,802(2.8)%Total Codman Specialty Surgical 283,135 280,6640.9% Wound Reconstruction and Care 79,648 74,7796.5%Private Label 29,135 27,2107.1%Total Tissue Technologies 108,783 101,9896.7%Total reported revenues$391,918 $382,6532.4% Impact of changes in currency exchange rates (4,452) — Total organic revenues(1)$387,467 $382,6531.3% (1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products. Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)Three Months Ended March 31, 2026 ItemTotal AmountCOGS(a)SG&A(b)R&D(c)Amort (d)OI&E(e)Tax(f)Acquisition, divestiture and integration-related charges
9,286 2,5886,120578——— EU Medical Device Regulation charges7,887
1,153
3,338
3,397
—
—
—
Boston Recall/Braintree Transition7,728
7,135
575
19
—
—
—
Intangible asset amortization expense27,005
23,230
—
—
3,775
—
—
Estimated income tax impact from above adjustments and other items
(7,541
)
—
—
—
—
—
(7,541
)
Depreciation expense11,235
—
—
—
—
—
—
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit) Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands) Three Months Ended March 31, 2025 ItemTotal AmountCOGS(a)SG&A(b)R&D(c)Amort (d)OI&E(e)Tax(f)Acquisition, divestiture and integration-related charges
26,473 22,769—— 3,704—— Estimated income tax impact from above adjustments and other items
(12,167)——— ——(12,167)Depreciation expense
10,456 ——— ——— a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit) RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands)
Three Months Ended March 31, 2026 2025 GAAP net loss$(4,617) $(25,293)Non-GAAP adjustments: Depreciation and intangible asset amortization expense 38,240 36,929 Other (income) expense, net (4,480) (320)Interest expense, net 18,118 14,394 Income tax expense 2,208 (4,743)Structural optimization charges 9,286 10,663 EU Medical Device Regulation charges 7,887 10,944 Boston Recall/Braintree Transition 7,728 14,810 Acquisition, divestiture and integration-related charges 1,812 6,224 Total of non-GAAP adjustments 80,799 88,902 Adjusted EBITDA$76,182 $63,609 RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
(In thousands, except per share amounts)
Three Months Ended March 31, 2026 2025 GAAP net loss$(4,617) $(25,293)Non-GAAP adjustments: Structural optimization charges 9,286 10,663 Acquisition, divestiture and integration-related charges 1,812 6,224 EU Medical Device Regulation charges 7,887 10,944 Boston Recall/Braintree Transition 7,728 14,810 Intangible asset amortization expense 27,005 26,473 Estimated income tax impact from adjustments and other items (7,541) (12,167)Total of non-GAAP adjustments 46,177 56,947 Adjusted net income$41,560 $31,654 Adjusted diluted net income per share$0.54 $0.41 Weighted average common shares outstanding for diluted net income per share 77,198 76,586 CONDENSED BALANCE SHEET DATA
(UNAUDITED) (In thousands)
March 31,
2026 December 31,
2025 Short term investments$28,693 $28,693Cash and cash equivalents 236,809 235,048Trade accounts receivable, net 264,413 278,849Inventories, net 495,035 492,735 Current and long-term borrowing under senior credit facility 1,789,005 1,768,306Borrowings under securitization facility 76,400 87,800Convertible securities — — Stockholders' equity$1,042,406 $1,043,463 CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED) (In thousands)
Three Months Ended March 31, 2026 2025 Net cash (used) provided by operating activities$9,803 $(11,257)Net cash used in investing activities (14,848) (35,920)Net cash provided by financing activities 8,297 35,377 Effect of exchange rate changes on cash and cash equivalents (1,491) 4,529 Net decrease in cash and cash equivalents$1,761 $(7,271) RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands) Three Months Ended March 31, 2026 2025 Net cash provided by operating activities$9,803 $(11,257) Purchases of property and equipment (14,848) (28,920)Free cash flow$(5,045)$(40,177) Adjusted net income(1)$41,560 $31,654 Adjusted free cash flow conversion (12.1)% (126.9)% Twelve Months Ended March 31, 2026 2025 Net cash provided by operating activities$71,445 $102,368 Purchases of property and equipment (67,365) (117,872)Free cash flow$4,080 $(15,504) Adjusted net income(1)$181,287 $185,652 Adjusted free cash flow conversion 2.3% (8.4)% (1) Adjusted net income for quarters ended March 31, 2026 and 2025 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations. The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION
(UNAUDITED) (In thousands) March 31,
2026December 31,
2025Short-term borrowings under senior credit facility$38,750 $38,750 Long-term borrowings under senior credit facility 1,750,255 1,729,556 Borrowings under securitization facility 76,400 87,800 Convertible securities — — Deferred financing costs netted in the above 2,870 3,257 Short term investments (28,693) (28,693)Cash & Cash Equivalents (236,809) (235,048)Net Debt$1,602,773 $1,595,622 RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP GROSS PROFIT TO MEASURES OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(UNAUDITED)
(In thousands, except percentages)
Three Months Ended March 31, 2026 2025 Total revenues, net$391,918 $382,653 Cost of goods sold 174,936 188,221 Reported Gross Profit 216,982 194,432 Structural optimization charges 2,588 4,276 Acquisition, divestiture and integration-related charges 28 671 Boston Recall/Braintree Transition 7,135 14,386 EU Medical Device Regulation 1,153 1,375 Intangible asset amortization expense 23,230 22,769 Adjusted Gross Profit$251,116 $237,909 Total Revenues$391,918 $382,653 Adjusted Gross Margin 64.1% 62.2%
Integra LifeSciences (IART - Free Report) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +32.78%. A quarter ago, it was expected that this medical device maker would post earnings of $0.79 per share when it actually produced earnings of $0.83, delivering a surprise of +5.06%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $391.92 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.74%. This compares to year-ago revenues of $382.65 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Integra shares have lost about 14.3% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for Integra?While Integra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Integra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.54 on $424.24 million in revenues for the coming quarter and $2.34 on $1.67 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Stereotaxis Inc. (STXS - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 12.
This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +28.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stereotaxis Inc.'s revenues are expected to be $9.1 million, up 21.8% from the year-ago quarter.
For the quarter ended March 2026, Integra LifeSciences (IART - Free Report) reported revenue of $391.92 million, up 2.4% over the same period last year. EPS came in at $0.54, compared to $0.41 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $381.46 million, representing a surprise of +2.74%. The company delivered an EPS surprise of +32.78%, with the consensus EPS estimate being $0.41.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Organic Revenue Growth: 1.3% versus -1.9% estimated by two analysts on average.Revenue- Tissue Technologies- Wound Reconstruction and Care: $79.65 million versus $70.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.5% change.Revenue- Tissue Technologies- Total: $108.78 million versus the two-analyst average estimate of $99.48 million. The reported number represents a year-over-year change of +6.7%.Revenue- Codman Specialty Surgical- Total: $283.14 million versus $281.62 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.Revenue- Tissue Technologies- Private Label: $29.14 million compared to the $28 million average estimate based on two analysts. The reported number represents a change of +7.1% year over year.View all Key Company Metrics for Integra here>>>
Shares of Integra have returned +14.4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Integra LifeSciences (IART - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Integra is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For Integra, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for IntegraFor the fiscal year ending December 2026, this medical device maker is expected to earn $2.38 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Integra. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.2%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Integra to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT.
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
3 Undervalued Midcaps Ready to PopIntegra LifeSciences NASDAQ: IART is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.
Knight said the company’s board and former CEO Mojdeh Poul reached a mutual decision for Poul to step down. She said Stuart has backed the operational transformation work already underway, including efforts to strengthen operational capabilities and quality management systems.
Get Integra LifeSciences alerts:
“Those are initiatives led by Mojdeh Poul, but they had the approval of the Board, and Stuart has also given it his full force and backing,” Knight said.
She added that the company’s focus areas — neurosurgery, tissue reconstruction and ENT — will remain unchanged. Knight said those markets represent a total addressable market of about $9 billion, with Integra operating in niche categories where it is generally ranked first or second.
Integra Points to Lower Volatility After Q1 Results Knight said Integra’s first-quarter results offered an early proof point that its transformation efforts are gaining traction. The company reported revenue and earnings per share above the high end of its guidance, which Knight said reflected operational improvements.
She said internal indicators supporting management’s confidence include fewer and less severe supply disruptions, better visibility from a supply chain “control tower,” improved yields and stronger external regulatory audit results. Cash flow also improved meaningfully in the first quarter, she said.
“As we measure all of these indicators, what we’re seeing, in fact, is it is helping to lower the volatility, which is going to be the key to allow us to perform more consistently from a growth perspective,” Knight said.
Knight reiterated that the company views its recent challenges as supply-related rather than demand-related. She said Integra does not expect to expand its commercial sales force in the near term, instead focusing on consistent product supply, returning products to market and using analytical tools to improve commercial execution.
Braintree Facility and SurgiMend Relaunch in Focus Discussing manufacturing, Knight said issues at Integra’s Boston facility stemmed from “an accumulation of gaps” in the quality management system that were compounded by the physical limitations of the site. By contrast, she described the Braintree facility as a “world-class tissue manufacturing facility” designed to improve process flow and efficiency.
Knight said Integra has revamped its quality management system, reduced manual processes, validated manufacturing protocols and added new leadership at the site. The company remains on track to operationalize Braintree in June, build inventory in the third quarter and support a fourth-quarter launch of SurgiMend back into the market.
She said the market for surgical matrices in breast reconstruction is about $800 million and growing at double-digit rates. Knight also said market trends have become more favorable for Integra, including a shift away from human ADM toward xenografts and resorbable synthetics, areas aligned with SurgiMend and DuraSorb.
Integra expects to pursue PMA labels for SurgiMend and DuraSorb in implant-based breast reconstruction, with Knight saying the company expects those in 2027. She said the relaunch strategy will be “phased and disciplined,” beginning with key prior users.
PriMatrix Relaunch and Reimbursement Dynamics Knight said Integra is pleased with the relaunch of PriMatrix, which returned to the market in the fourth quarter of 2025 after being off the market for more than two years. She said the initial launch was controlled, with broader expansion in the first quarter, and performance has been consistent with expectations.
Some prior users have returned, while others want Integra to continue demonstrating reliable supply, Knight said. She added that the company does not believe it needs to meaningfully change pricing to regain share because of product differentiation and clinical trust.
On wound care reimbursement, Knight said about 90% of Integra’s business is in the inpatient acute setting, where reimbursement under DRGs has not changed. She said wound reconstruction products delivered double-digit growth in the first quarter.
For the approximately 10% of the business in outpatient settings, Knight said Integra has not seen the same disruption as others. She pointed to the company’s product price, size options and clinical evidence, noting that Integra was already priced in line with the current reimbursement rate of $127 per square centimeter.
Growth Outlook, ENT Pressures and Capital Allocation Knight said both tissue reconstruction and specialty surgery are expected to contribute to growth, though tissue reconstruction is expected to grow faster as supply reliability improves and products return to the market. She said SurgiMend should contribute to growth in 2026, with PMA labels for SurgiMend and DuraSorb expected to support further growth in 2027.
In ENT, Knight said Integra continues to face reimbursement-related headwinds in balloon sinuplasty, which affected results in 2025 and are expected to continue into 2026. She said growth opportunities are stronger in navigation systems and Eustachian tube products, which could eventually help return ENT to a mid-single-digit to high-single-digit growth trajectory.
On capital allocation, Knight said debt repayment remains the priority. Integra is targeting a leverage range of 2.5 times to 3.5 times, and Knight said the company expects to be just outside the upper end of that range by the end of 2026 and within the range in 2027.
Knight said M&A could eventually return to the strategy, but only after operations stabilize and cash flow improves. Potential deals would likely be tuck-in to midsize opportunities in neurosurgery, tissue reconstruction, ENT or adjacent markets.
Tariffs, Cost Savings and Cash Flow Knight said Integra recorded a $0.10 first-quarter EPS benefit relative to guidance from tariffs. That included a $0.03 refund for prior-year tariffs and $0.07 of avoided tariff expense after IEEPA tariffs were ruled unlawful.
For the full year, Integra now expects tariff impacts of about $0.10 to EPS, compared with a prior expectation of $0.32. Knight said the company has not reflected a potential additional $0.12 benefit in guidance because tariff policy remains uncertain.
Integra has identified $25 million to $30 million in cost savings initiatives that Knight said are fully implemented. The savings come from manufacturing efficiencies, yield improvements, operating model changes and lower third-party costs in SG&A.
Knight said the company is targeting operating cash flow of $200 million for the year, an improvement of $150 million, and free cash flow of about $140 million after negative free cash flow in the prior year. She cited improved EBITDA, working capital gains, lower EU MDR and Braintree startup spending, and normalized capital expenditures as drivers.
“It feels good to see evidence that the transformation is working,” Knight said in closing. “We still have a lot of work to do.”
About Integra LifeSciences NASDAQ: IARTIntegra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Integra LifeSciences Right Now?Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Tissue Technologies.
IART is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. IART has a Momentum Style Score of B, and shares are up 26.6% over the past four weeks.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.10 to $2.42 per share. IART boasts an average earnings surprise of +16.8%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IART should be on investors' short list.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Integra LifeSciences (IART - Free Report) Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. In its first-quarter 2026 report, the company renamed two of its segments: Codman Specialty Surgical was renamed Specialty Surgery, while Tissue Technologies was renamed Tissue Reconstruction.
IART is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 6.25; value investors should take notice.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.10 to $2.42 per share. IART also boasts an average earnings surprise of +16.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IART should be on investors' short list.
Key Takeaways DaVita's dialysis business and Integrated Kidney Care momentum support its long-term growth outlook.Integra benefits from stronger Specialty Surgery demand and improved supply execution momentum.LyondellBasell and Braskem pair discounted valuations with solid long-term growth expectations. In the equity market, investors often seek strategies that can balance risk and reward, especially during periods of heightened volatility and economic uncertainty. While some investors favor deeply discounted value stocks and others pursue high-growth opportunities, a blended approach has increasingly proven effective in navigating changing market conditions.
This has led to the growing popularity of the GARP (growth at a reasonable price) strategy, which combines the core principles of value and growth investing. Rather than focusing solely on undervalued stocks or aggressive growth plays, GARP investors look for companies that offer sustainable earnings growth while still trading at attractive valuations. The approach aims to capture long-term upside potential without overpaying for momentum-driven stocks.
The success of this hybrid investing strategy has been evident in several outperforming stocks across sectors in recent years. Companies with strong fundamentals, resilient earnings growth and reasonable valuations have delivered substantial returns, highlighting the effectiveness of balancing value with growth characteristics. Here, we discuss four such stocks: DaVita (DVA - Free Report) , Integra LifeSciences (IART - Free Report) , Braskem (BAK - Free Report) and LyondellBasell Industries (LYB - Free Report) .
A Few More Words on GARPGARP investing gives priority to one of the popular value metrics, the price/earnings growth (PEG) ratio. Although it is categorized under value investing, this strategy follows the principles of both growth and value investing.
The PEG ratio is defined as (Price/ Earnings)/Earnings Growth Rate.
It relates the stocks’ P/E ratios to the future earnings growth rates.
While P/E alone gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps identify stocks with solid future potential.
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Say, for example, if a stock's P/E ratio is 10 and the expected long-term growth rate is 15%, the company's PEG will come down to 0.66, a ratio indicating both undervaluation and future growth potential.
Unfortunately, this ratio is often neglected due to investors' limitations in calculating the future earnings growth rate of a stock.
There are some drawbacks to using the PEG ratio, though. It does not consider the very common situation of changing growth rates, such as the forecast of the first three years at a very high growth rate, followed by a sustainable but lower growth rate over the long term.
Hence, PEG-based investing can be even more rewarding if some other relevant parameters are also taken into consideration.
Here are the screening criteria for a winning strategy:
PEG Ratio less than X Industry Median
P/E Ratio (using F1) less than X Industry Median (For more accurate valuation purposes)
Zacks Rank #1 (Strong Buy) or 2 (Buy) (Whether good market conditions or bad, stocks with a Zacks Rank #1 or #2 have a proven history of success.)
Market Capitalization greater than $1 Billion (This helps us to focus on companies that have strong liquidity.)
Average 20-Day Volume greater than 50,000: A substantial trading volume ensures that the stock is easily tradable.
Percentage Change F1 Earnings Estimate Revisions (4 Weeks) greater than 5%: Upward estimate revisions add to the optimism, suggesting further bullishness.
Value Score of less than or equal to B: Our research shows that stocks with a Value Style Score of A or B, when combined with a Zacks Rank #1, 2 or 3 (Hold), offer the best upside potential.
Growth Score of less than or equal to B: Our research shows that stocks with a Growth Style Score of A or B, when combined with a Zacks Rank #1, 2 or 3, offer the best upside potential.
Our PEG-Driven PicksHere are four stocks that qualified for the screening:
DaVita: Headquartered in Denver, CO, DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease. Its U.S. dialysis segment remains the primary earnings driver, supported by steady reimbursement and cost control. Management also highlighted continued momentum within the Integrated Kidney Care during first-quarter 2026
DVA can be an impressive GARP investment pick with its Zacks Rank #1, a Value Score of B and a Growth Score of B. Apart from a discounted PEG and P/E, the stock has an impressive long-term expected growth rate of 20.2%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Integra: Headquartered in Plainsboro, NJ, Integra LifeSciences Holdings Corporation is one of the world leaders in regenerative medicine. The company develops, manufactures and markets surgical implants and medical instruments. Integra is seeing steadier demand in Specialty Surgery, supported by its neurosurgery franchise and a broader ENT platform from Acclarent, while improving supply execution is helping conversion and capital equipment placements.
IART has a Zacks Rank #2, a Value Score of B and a Growth Style Score of B. Integra also has a five-year expected growth rate of 5.9%.
Braskem: Braskem manufactures and sells petrochemicals, thermoplastic resins and fuels in Brazil and international markets. Its portfolio includes polyethylene, polypropylene, PVC and basic chemicals, along with utilities, industrial services, electricity and natural gas supply.
BAK stock can be an impressive GARP investment pick with its Zacks Rank #2, a Value Score of A and a Growth Score of B. Apart from a discounted PEG and P/E, Braskem has an impressive long-term expected growth rate of 16.8%.
LyondellBasell: Based in Houston, TX, LyondellBasell is among the leading plastics, chemical and refining companies globally with operations across 18 countries. The company’s products are used across various industries, including electronics, automotive parts, packaging, construction materials and biofuels.
LYB can also be an impressive GARP investment pick with its Zacks Rank #1, a Value Score of B and a Growth Score of B. Apart from a discounted PEG and P/E, the stock also has a solid long-term historical growth rate of 49.4%.
Have you been paying attention to shares of Integra LifeSciences (IART - Free Report) ? Shares have been on the move with the stock up 56.2% over the past month. The stock hit a new 52-week high of $16.62 in the previous session. Integra has gained 32.5% since the start of the year compared to the -4.5% move for the Zacks Medical sector and the -15.5% return for the Zacks Medical - Instruments industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 5, 2026, Integra reported EPS of $0.54 versus consensus estimate of $0.41 while it beat the consensus revenue estimate by 2.74%.
For the current fiscal year, Integra is expected to post earnings of $2.42 per share on $1.67 in revenues. This represents a 8.52% change in EPS on a 2.24% change in revenues. For the next fiscal year, the company is expected to earn $2.57 per share on $1.73 in revenues. This represents a year-over-year change of 6.3% and 3.27%, respectively.
Valuation MetricsIntegra may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Integra has a Value Score of B. The stock's Growth and Momentum Scores are B and D, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 6.8X current fiscal year EPS estimates, which is not in-line with the peer industry average of 22.7X. On a trailing cash flow basis, the stock currently trades at 3.9X versus its peer group's average of 15.3X. Additionally, the stock has a PEG ratio of 1.15. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Integra currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Integra fits the bill. Thus, it seems as though Integra shares could have a bit more room to run in the near term.
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET.
A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART - Free Report) and Masimo . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Integra LifeSciences and Masimo are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This means that IART's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
IART currently has a forward P/E ratio of 6.48, while MASI has a forward P/E of 30.99. We also note that IART has a PEG ratio of 1.10. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MASI currently has a PEG ratio of 1.81.
Another notable valuation metric for IART is its P/B ratio of 1.17. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, MASI has a P/B of 11.86.
Based on these metrics and many more, IART holds a Value grade of B, while MASI has a Value grade of D.
IART sticks out from MASI in both our Zacks Rank and Style Scores models, so value investors will likely feel that IART is the better option right now.
